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Abstract
Background: We aimed to explore the association of clinical symptoms of COVID-19 pneumonia, blood pa-
rameters on admission, and anti-hypertensive drugs with in-hospital outcomes, including length of hospital and 
intensive care unit (ICU) stay, receiving mechanical ventilation, degree of lung injury, and in-hospital death among 
patients with hypertension.
Material and methods: This retrospective study conducted in patients with newly diagnosed COVID-19 pneumo-
nia from August 20, 2020 to September 25, 2020.
Results: A total of 182 patients with COVID-19 pneumonia were included in the present study. The patients 
were categorized into those with hypertension (n = 82) or without hypertension (n = 100). Patients on angiotensin 
receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) showed no significant increase 
in the risk for all in-hospital outcomes. Old age [0.6 (0.5–2) p < 0.00], fever [0.3 (0.2–1.8), p < 0.00] and low 
lymphocytes percentage [0.3 (0.2–1.2), p < 0.00] were associated with increased risk for extensive lung injury. 
Old age [0.4 (0.1 = 0.7) p < 0.01], high neutrophil count [0.3 (0.2–2), p = 0.02] and low lymphocyte percentage  
[0.3 (0.1–0.7), p = 0.01] were associated with prolonged hospital stay while low lymphocytes percentage [0.7 (0.6–0.9), 
p < 0.00], old age [1.2 (1–1.4), p = 0.01] and fatigue [2 (1–4), p = 0.04] showed significant association with prolonged 
length of ICU stay. Low lymphocytes percentage [0.7 (0.6–1), p < 0.00], old age [1.1 (1–1.2), p = 0.01] and fatigue  
[2 (1.7–4), p = 0.02] were associated with increased risk for receiving mechanical ventilation. Risk for in-hospital 
death was associated with increased neutrophil percentage [1.2 (1–1.5), p = 0.01] and old age [1.1 (1–1.2), p = 0.03].
Conclusions: ARBs and ACEIs showed no significant association with adverse in-hospital outcomes. Old age, low 
lymphocytes percentage and high neutrophils percentage on admission were independent predictors for increased 
risk of in-hospital mortality and morbidity among COVID-19 pneumonia patients with hypertension.
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Introduction
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV2), was identified as the cause of an out-
break of acute respiratory illness in Wuhan City, 
China. The World Health Organization (WHO) de-
clared that the SARS CoV-2 causes the CoV disease 
2019 abbreviated as COVID-19 [1, 2]. The severity 
of the COVID-19 infection can vary from patient 
to patient. Some cases of COVID-19 infection were 
associated with pneumonia and shortness of breath. 
On the other hand, some patients developed respira-
tory failure, septic shock, or multiple organ failure 
leading to death [2–4]. 
Previous clinical studies and reports on SARS and 
Middle East respiratory syndrome found that hyper-
tension is associated with increased rate of morbidity 
and mortality in infected patients [5, 6].
Emerging data about COVID-19 pandemic re-
ports that the morbidity and mortality rates of CO-
VID-19 infection in patients with cardiovascular dis-
eases, including hypertension, are much higher than 
those of patients without comorbidities [7, 8]. The 
available evidence has suggested that COVID-19 se-
verity and prognosis are significantly associated with 
cardiovascular disorders, but the specific mechanisms 
and link between the two are unclear [8]. Some 
initial reports have suggested that hypertension or 
its treatment may be involved in the pathogenesis 
and progression of COVID-19 due to interaction 
between SARS-COV-2 and angiotensin-converting 
enzyme 2 (ACE2), a potential receptor for SARS-
COV-2 to enter human cells [2, 9]. However, the 
potential effects of hypertension and its treatment 
on COVID-19 pneumonia severity and prognosis 
remain an area for active research. Also, there is lim-
ited evidence that determines the predictors of poor 
outcomes among COVID-19 pneumonia patients 
with hypertension during in-hospital course.
The main aim of the present study was to explore 
the association of clinical symptoms of COVID-19 
pneumonia, blood parameters on admission, and 
anti-hypertensive drugs with in-hospital adverse out-
comes, including length of hospital and intensive 
care unit (ICU) stay, receiving mechanical ventila-
tion, degree of lung injury, and in-hospital death 
among patients with hypertension.
Material and methods
In this retrospective study, we recruited patients with 
newly diagnosed COVID-19 infection who pre-
sented with features suggestive of pneumonia to the 
Al-Sader teaching hospital in Al-Najaf governorate 
from August 20, 2020 to September 25, 2020. All 
patients were presented with features consistent with 
COVID-19 pneumonia based on clinical symptoms 
(fever, dry or productive cough, fatigue, or short-
ness of breath) and radiological findings. Diagnosis 
of COVID-19 infection was based on positive na-
sopharyngeal swab by real time polymerase chain 
reaction (PCR). At hospital admission, the baseline 
clinical characteristics and complete blood count 
were recorded using medical records and collected 
by attending physicians. The baseline clinical char-
acteristics including age, sex, hypertension, diabetes 
mellitus, smoking, body mass index (BMI), previ-
ous coronary artery disease, anti-hypertensive drugs, 
complete blood count, and in-hospital clinical out-
come. Complete blood parameters included white 
blood cell count (WBC), lymphocyte count and per-
centage, neutrophil count and percentage, red blood 
cell count (RBC), hemoglobin (Hb), red blood cell 
mean volume (MCV), red blood cell width distri-
bution (RDW), platelet count, platelet distribution 
width (PDW), and platelet mean volume (PMV). 
Patients who were receiving antihypertensive therapy 
with the diagnosis of hypertension at the time of hos-
pital admission were labeled as patients with hyper-
tension. The severity of lung injury by COVID-19 
pneumonia was assessed by CT scan examination 
score at the time of hospital admission. Patients were 
followed up in hospital until discharged or died. The 
main in-hospital outcome for the study was defined 
as receiving mechanical ventilation, length of hos-
pital and ICU stay, degree of lung injury according 
to CT score and in-hospital death. Approval of this 
study was provided by our medicine College Board.
Statistical analysis
Statistical analysis was performed using SPSS ver. 
23.0 (SPSS Inc., Chicago, IL, USA). P-value of 
< 0.05 was chosen for statistical significance. Baseline 
clinical data of the patients and blood parameters 
were expressed as mean ± standard deviation for 
continuous variables and compared by Student t-test 
or as numbers with percentages for categorical data 
and compared by chi-square test. Univariate analysis 
was used to calculate the odds ratio and confidence 
intervals [OR (CI)] and assess the association of 
anti-hypertensive drugs with in-hospital outcomes. 
Baseline clinical characteristics, including age, sex, 
diabetes mellitus, smoking, body mass index (BMI), 
previous coronary artery disease, clinical symptoms 
on admission and complete blood parameters under-
went univariable logistic regression to the in-hospital 
outcomes. Those with a p value of < 0.05 were found 
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eligible for inclusion in the final multivariable lo-
gistic regression analysis to assess their independent 
association with in-hospital outcome.
Results
A total of 182 patients with COVID-19 pneumonia 
were included in the present study. The patients were 
categorized into those with hypertension [age (years) 
58 ± 9, 33 (40%) were males] or without hyperten-
sion [age (years) 42 ± 15, 49 (49%) were males). 
In patients with hypertension, fever was the most 
common clinical symptom followed by dry cough, 
shortness of breath, fatigue, productive cough, taste 
and smell loss. Thirty nine (48%) patients with hy-
pertension were on angiotensin receptor blockers 
(ARBs) while 18 (22%) patients were on angioten-
sin-converting enzyme inhibitors (ACEIs). Patients, 
characteristics are shown in Table 1.
Patients with hypertension were older (58 year 
versus 42 year, p < 0.00) and had higher BMI val-
ues (30 versus 28, p = 0.01) than patients without 
hypertension. The prevalence of diabetes mellitus 
(p < 0.00), smoking (p = 0.02), coronary artery 
disease (p < 0.00) was higher among patients with 
hypertension compared to patients without hyper-
tension. Shortness of breath (p < 0.00) and loss of 
smell and taste (p < 0.00) were more frequently 
observed among patients with hypertension while no 
significant change in the frequency of fever, dry and 
productive cough, and fatigue between the groups 
with and without hypertension. Regarding blood 
parameters distribution, higher values of white blood 
cells (1000 vs. 8000, p = 0.03), neutrophil count 
(8000 vs. 5000, p < 0.00), neutrophil percentage 
(77 vs. 62, p < 0.00), and PDW (13 vs. 12, p = 0.01) 
and lower values of lymphocyte count (1.4 vs. 2.3, 
p < 0.00) and lymphocytes percentage (16 vs. 29, 
p < 0.00) were observed among patients with hyper-
tension compared to patients without hypertension. 
With the exception of in-hospital death, the remain-
ing in-hospital outcomes, including length of hospi-
tal and ICU stay, receiving mechanical ventilation, 
and lung injury were more common in patients with 
hypertension than patients without hypertension 
(p < 0.00) (Tab. 1).
Predictors of in-hospital outcome 
among patients with hypertension 
Patients on ARBs and ACEIs showed no significant 
increase in the risk for all in-hospital outcomes in 
univariate analysis (Tab. 2) Baseline clinical symp-
toms, comorbidities and blood parameters which 
were significant in univariate analysis were selected 
for final multivariate analysis.
Old age [0.6 (0.5–2), p < 0.00], fever [0.3 (0.2–1.8), 
p < 0.00] and low lymphocyte percentage [0.3 
(0.2–1.2), p < 0.00] were associated with increased 
risk for extensive lung injury as assessed by CT scan 
examination. Old age [0.4 (0.1–0.7), p < 0.01], in-
creased neutrophil count [0.3 (0.2–2), p = 0.02] and 
low lymphocyte percentage [0.3 (0.1–0.7), p = 0.01] 
were associated with prolonged hospital stay while 
low lymphocyte percentage [0.7 (0.6–0.9), p < 0.00], 
old age [1.2 (1–1.4), p = 0.01] and fatigue [2 (1–4), 
p = 0.04] showed significant association with pro-
longed length of ICU stay. Low lymphocyte percent-
age [0.7 (0.6–1), p < 0.00], old age [1.1 (1–1.2), 
p = 0.01] and fatigue [2 (1.7–4), p = 0.02] were as-
sociated with increased risk for receiving mechanical 
ventilation. Risk for in-hospital death was associated 
with increased neutrophil percentage [1.2 (1–1.5), 
p = 0.01] and old age [1.1 (1–1.2), p = 0.03].
Discussion 
The major findings of our study were: (1) compara-
tive analysis of COVID-19 pneumonia patients 
with and without hypertension showed that patients 
with hypertension had higher prevalence of age > 45 
year, obesity, diabetes mellitus, history of coronary 
artery disease, and smoking than patients without 
hypertension; (2) in-hospital outcomes, including 
length of hospital and ICU stay, receiving mechani-
cal ventilation, and lung injury were more common 
in patients with hypertension than patients without 
hypertension(p < 0.00); (3) ARBs and ACEIs were 
not associated with increased risk of adverse in-hos-
pital outcome; (4) old age, low lymphocyte percent-
age, and high neutrophil count and percentage were 
associated with increased risk for adverse in-hospital 
outcome among patients with hypertension.
During the previous outbreak of Middle East Re-
spiratory Syndrome (MERS), Metabolic disorders 
and clinical predictors of morbidity and mortality 
outcomes among MERS-CoV infected patients were 
hypertension, old age, diabetes, obesity, and coro-
nary artery disease. These comorbidities can be in-
volved or linked etiologically to the pathogenesis 
of MERS-CoV through modulating the innate im-
mune response of the host [1, 10, 11].
According to data from china, COVID-19 pa-
tients with metabolic disorders showed adverse clini-
cal outcome [2, 12]. It is speculated that systemic 
inflammation may be the major factor for develop-
ment and progression of COVID‐19. Several studies 
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have been reported that patients with underlying 
chronic metabolic disorders, such as diabetes, obe-
sity and hypertension, can modulate the function of 
the innate and humoral immune systems leading to 
Table 1. Patients characteristics
Variables Hypertension(n = 82) 
Without hypertension 
(n = 100) p value
Age (years) 58 ± 9 42 ± 15 < 0.00
Male sex, n (%) 33 (40%) 49 (49%) 0.23
Diabetes mellitus, n (%) 41 (50%) 19 (19%) < 0.00
Smoking 20 (24%) 12 (12%) 0.02
Coronary artery disease, n (%) 19 (23%) 4 (4%) < 0.00
BMI 30 ± 5 28 ± 4 0.01
Fever, n (%) 70 (85%) 82 (82%) 0.54
Dry cough, n (%) 63 (77%) 75 (75%) 0.77
Productive cough, n (%) 23 (28%) 24 (24%) 0.53
Smell loss, n (%) 14 (17%) 43 (43%) < 0.00
Taste loss, n (%) 18 (22%) 45 (45%) < 0.00
Fatigue, n (%) 37 (45%) 45 (45%) 0.98
Shortness of breath, n (%) 56 (68%) 47 (47%) < 0.00
Anti-hypertension drugs
ARBs, n (%) 39 (48%) – –
ACEIs, n (%) 18 (22%) – –
Ca channel blockers, n (%) 18 (22%) – –
Beta-blockers, n (%) 8 (10%) – –
> one drug, n (%) 15 (18%) – –
Blood parameters
WBCs [× 109/L] 10 ± 5 8 ± 3 0.03
Lymphocyte (%) 16 ± 5 29 ± 13 < 0.00
Neutrophil (%) 77 ± 10 62 ± 17 < 0.00
Lymphocyte count [× 109/L] 1.4 ± 0.5 2.3 ± 1 < 0.00
Neutrophil count [× 109/L] 8 ± 3 5 ± 2 < 0.00
Neutrophil/lymphocyte 7 ± 0.9 5 ± 1 0.22
Platelet/lymphocyte 196 ± 15 200±33 0.91
RBC [106/μL] 4.5 ± 0.6 4.6±0.6 0.25
Hb [g/dL] 12 ± 2 13 ± 2 0.31
MCV [fl] 85 ± 7 87 ± 60 0.11
RDW (%) 45 ± 4 44 ± 4 0.78
Platelet count [× 109/L] 251 ± 50 264 ± 25 0.57
PDW (%) 13 ± 3 12 ± 2 0.01
PMV (fl) 9 ± 1 9.1 0.13
In-hospital outcomes
In-hospital death, n (%) 13 (19%) 9 (9%) 0.15
Hospital stay [day] 9 ± 2 3 ± 1 <  0.00
ICU stay [day] 6 ± 1 3 ± 1 <0.00
Lung injury 42 ± 22 20 ± 12 < 0.00
Mechanical ventilation use, n (%) 26 (31%) 12 (12%) < 0.00
ARB — angiotensin receptor blocker; ACEI — angiotensin-converting enzyme inhibitor; BMI — body mass index; ICU — intensive care unit; MCV — mean cell volume; PDW — platelet 
distribution width; PMV — platelet mean volume; RDW — red blood cell distribution width; WBCs — white blood cells
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lungs [2, 14]. Patients with hypertension, diabetes 
and coronary artery disease are the most consumers 
of ACEIs and ARBs. There is evidence from experi-
mental studies that inhibition of ACE2 production 
by negative feedback from the use of ACEIs and 
ARBs for treatment of hypertension and other car-
diovascular diseases increases the expression of the 
ACE2 receptors particularly in the cardiac tissues, 
thus increasing the availability of target molecules for 
SARS-CoV-2 [2, 15]. However, the upregulation in 
ACE2 following ARB or ACEI use is observed after 
high dose administration of these drugs in animals 
and not in doses commonly used in humans. Also, 
this upregulation has been documented mainly in 
cardiac tissues and not in the lungs [16].
In our study, ARBs and ACEIs showed no signifi-
cant association with adverse in-hospital outcome, 
although about 70% of patients with hypertension 
enrolled in the study were on ACEIs or ARBs prior 
to hospital admission. In the literature, the role of 
ARBs and ACEIs in the pathogenesis and severity 
of COVID-19 infection is obscure and controversial 
[8]. In the early phase of COVID-19 infection, there 
has been concern regarding the potential harmful role 
of ACEIs and ARBs based on previous animal studies 
showing that these drugs could alter tissue expression 
of ACE2 leading to enhance susceptibility to viral 
host cell entry and propagation [17]. On the other 
hand, no effect of ACEIs or ARBs on ACE2 activity 
was found in recent reports [14, 18]. Consistent with 
our results, Guo et al. reported that ARB and ACEI 
use was not associated with increased patients’ mor-
tality rate, although more patients were using ACEI 
and ARB medications prior to COVID-19 infection 
[19]. Also, use of ACEI or ARB among hospitalized 
COVID-19 patients with hypertension was associ-
ated with lower risk of all-cause mortality compared 
with ACEI/ARB non-users [8, 20]. 
Regarding blood parameters’ role in COVID-19 
patients with hypertension, low lymphocyte count 
or percentage and high neutrophil count or per-
centage may be considered as a cardinal finding in 
COVID-19 infection with prognostic implication 
in determining disease severity and progression [21]. 
cytokines imbalance and chronic low-grade systemic 
inflammatory phenotype. As such, this chronic low-
grade systemic inflammation in COVID-19 patients 
who have underlying chronic diseases could promote 
systemic inflammatory response when SARS-CoV-2 
infected [8, 9, 13].
Another major mechanism by which COVID-19 
can lead to adverse outcome is via virus binding to 
ACE2 receptors, which is required for virus entry 
into target cells in the cardiovascular system and 
Table 2. Univariate analysis of angiotensin receptor blocker (ARBs) and angiotensin-converting enzyme inhibitor (ACEIs) with in-hospital 
outcome
Death Mechanical  ventilation use
Length of ICU  
stay
Length of hospital  
stay Lung injury










ICU — intensive care unit
Table 3. Multivariate regression* **
Lung injury
Predictor OR (CI) p value
Old age 0.6 (0.5–2) < 0.00
Fever on admission 0.3 (0.2–1.8) < 0.00
Low lymphocyte % 0.3 (0.2–1.2) < 0.00
Length of hospital stay
OR (CI) p value
Old age 0.4 (0.1–0.7) < 0.00
Low lymphocyte % 0.3 (0.1–0.7) 0.01
High neutrophil count 0.3 (0.2–2) 0.02
Length of ICU stay
OR (CI) p value
Low lymphocytes % 0.7 (0.6–0.9) < 0.00
Old age 1.2 (1–1.4) 0.01
Fatigue on admission 2 (1–4) 0.04
Mechanical ventilation use
OR (CI) p value
Low lymphocyte % 0.7 (0.6–1) < 0.00
Old age 1.1 (1–1.2) 0.01
Fatigue on admission 2 (1.7–4) 0.02
In-hospital death
OR (CI) p value
High neutrophil % 1.2 (1–1.5) 0.01
Old age 1.1 (1–1.2) 0.03
*significant variables, including baseline blood parameters, comorbidities and clinical 
symptoms with p value < 0.05 in the univariate logistic regression model were entered 
as predictors in the final multivariate regression model; **only variables significant with 
p value < 0.05 are displayed in the table; OR (CI) — odd ratio (confidence interval)
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High neutrophil count reflects the intensity of in-
flammatory response during COVID-19 pneumo-
nia, while low lymphocyte count reflects the damage 
of immune system and may perpetuate a harmful 
inflammatory status [22]. Chronic cardiovascular 
disease, such as hypertension, may influence neu-
trophils count and function [23]. The predictive role 
of lymphocyte and neutrophil counts in assessing 
the severity of COVID-19 pneumonia is consistent 
with previous reports that patients infected with 
SARS‐CoV‐2 had a high neutrophil count and a low 
lymphocyte count during the severe phase [24, 25]. 
In line with a previous report, Zhu Z et al. found 
that high level of peripheral blood cytokine IL-6, 
significant increase in neutrophil count, significant 
decrease in lymphocyte percentage, and hypertension 
were independent risk factors for assessing the sever-
ity of COVID-19 [22].
The present study has several limitations. The 
sample size was relatively small recruited from single 
hospital. The design of the study was retrospective, 
thus residual confounding might exist.
Conclusion
COVID-19 pneumonia patients with hypertension 
were likely to have adverse in-hospital outcomes 
compared to COVID-19 pneumonia patients with-
out hypertension. ARBs and ACEIs showed no 
significant association with adverse in-hospital out-
comes. Old age, low lymphocyte percentage and 
high neutrophil percentage on admission were inde-
pendent predictors for increased risk of in-hospital 
mortality and morbidity among COVID-19 pneu-
monia patients with hypertension.  
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